122 related articles for article (PubMed ID: 20143119)
1. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis.
Goto M
Mod Rheumatol; 2010 Jun; 20(3):238-43. PubMed ID: 20143119
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
3. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
5. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
6. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
[TBL] [Abstract][Full Text] [Related]
7. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.
Shirinsky I; Polovnikova O; Kalinovskaya N; Shirinsky V
Rheumatol Int; 2013 Dec; 33(12):3045-8. PubMed ID: 23263548
[TBL] [Abstract][Full Text] [Related]
8. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
9. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
11. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy studies].
Pedro-Botet J; Flores-Le Roux JA
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
[TBL] [Abstract][Full Text] [Related]
14. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate profiled as the fibrate with additional new data, supporting its use with statins in the European Medicines Agency recommendations.
Cardiovasc J Afr; 2011; 22(1):55. PubMed ID: 21298212
[No Abstract] [Full Text] [Related]
16. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis.
Lv S; Liu Y; Zou Z; Li F; Zhao S; Shi R; Bian R; Tian H
Clin Exp Rheumatol; 2015; 33(1):69-76. PubMed ID: 25327393
[TBL] [Abstract][Full Text] [Related]
17. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidaemia, statins and rheumatoid arthritis.
Nurmohamed MT; Dijkmans BA
Ann Rheum Dis; 2009 Apr; 68(4):453-5. PubMed ID: 19286903
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
